Find clinical trials for Leukemia in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near New Haven, CT, USA:
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
New Haven, Connecticut, United States and 23 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...
Phase 1
New Haven, Connecticut, United States and 20 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
New Haven, Connecticut, United States and 110 other locations
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...
Phase 3
Hawthorne, New York, United States and 69 other locations
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...
Phase 3
Southington, Connecticut, United States and 222 other locations
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...
Phase 2
Commack, New York, United States and 7 other locations
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
New Haven, Connecticut, United States and 125 other locations
drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia...
Phase 1
New Haven, Connecticut, United States and 10 other locations
of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...
Phase 1, Phase 2
New Haven, Connecticut, United States and 48 other locations
syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who are not eligible for intensive chemotherapy or hematopoietic...
Phase 3
New Haven, Connecticut, United States and 148 other locations
Clinical trials
Research sites
Resources
Legal